Moreover, analysis of the BEAT AML 2.0 cohort [12] revealed high FBXL6 mRNA expression levels to correlate with adverse prognosis according to the ELN guidelines [2] in further support of an oncogenic role (Supplementary Fig. 1C). This evidence concerns the gene FBXL6 and acute myeloid leukemia.